Beth A. Fleck

The Regulation of Feeding and Metabolic Rate and the Prevention of Murine Cancer Cachexia with a Small-Molecule Melanocortin-4 Receptor Antagonist

Stacy Markison, Alan C. Foster, Chen Chen et al. · Endocrinology · 2005 · 97 citations · Full text

Metabolic Rate, Food Intake, Metabolic Remodeling +18

Identification of Novel HSP90α/β Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington’s Disease

Justin T. Ernst, Timothy D. Neubert, Michael C. Liu et al. · Journal of Medicinal Chemistry · 2014 · 67 citations · Full text

Drug Target, Hsp90α/β Inhibitors, Molecular Biology +21

Binding Kinetics Redefine the Antagonist Pharmacology of the Corticotropin-Releasing Factor Type 1 Receptor

Beth A. Fleck, Sam R.J. Hoare, Rebecca R. Pick et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 62 citations

Functional Selectivity of Melanocortin 4 Receptor Peptide and Nonpeptide Agonists: Evidence for Ligand-Specific Conformational States

Sarah A. Nickolls, Beth A. Fleck, Sam R.J. Hoare et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 49 citations · Full text

The importance of target binding kinetics for measuring target binding affinity in drug discovery: a case study from a CRF1 receptor antagonist program

Sam R.J. Hoare, Beth A. Fleck, John P. Williams et al. · Drug Discovery Today · 2019 · 36 citations

Molecular Docking, Drug Target, Signal Transduction +8